Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0....
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and lowers the price target from $...
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0....
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time ...
RBC Capital analyst Luca Issi maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Outperform and raises the price target from $11 ...
